Share Name Share Symbol Market Type Share ISIN Share Description
Reneuron Group Plc LSE:RENE London Ordinary Share GB00BF5G6K95 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 109.50 0.00 01:00:00
Bid Price Offer Price High Price Low Price Open Price
107.00 112.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 6.07 -13.86 -35.90 62
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 109.50 GBX

Reneuron (RENE) Latest News

More Reneuron News
Reneuron Investors    Reneuron Takeover Rumours

Reneuron (RENE) Discussions and Chat

Reneuron (RENE) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Reneuron trades in real-time

Reneuron (RENE) Top Chat Posts

Reneuron Daily Update: Reneuron Group Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker RENE. The last closing price for Reneuron was 115p.
Reneuron Group Plc has a 4 week average price of 92p and a 12 week average price of 92p.
The 1 year high share price is 152p while the 1 year low share price is currently 72.50p.
There are currently 56,855,705 shares in issue and the average daily traded volume is 93,563 shares. The market capitalisation of Reneuron Group Plc is £62,256,996.98.
zho: FWIW: '@Stifel maintain their BUY recommendation for @ReNeuronPLC following the retinal Phase II trial announcement - "...any significant stock weakness on this news (now c.-11% to 109p vs. FTSE AIM All share 0%) is overdone..." Target price 400p
stutes: Today's news hrpc trial infection is another piece of misfortune for Rene. I think it's time for Rene to sell itself
goyathlay: Not exactly ideal! ""Released 11:55:07 09 June 2021 RNS Number : 3482B ReNeuron Group plc 09 June 2021 ReNeuron Group plc ("ReNeuron" or the "Company") Update for hRPC therapy candidate study ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, provides an update on the Company's Phase 2a clinical evaluations for the treatment of retinitis pigmentosa ('RP'), an inherited, degenerative eye disease. Further to the update on 15 January 2021, the Company has activated sites in Spain and the UK, to expand the Phase 2a extension study outside the US, thus representing a total of four actively enrolling sites worldwide. The most recently enrolled subject was treated last week, undergoing a successful surgical procedure to implant the hRPC drug product. Five days following treatment, the subject presented with a presumed bacterial intraocular infection in the treated eye which impacted their vision, and was treated initially with an appropriate regimen of antibiotics, to which they responded with clinical improvement. Systemic anti-inflammatory therapy was subsequently added, and the subject continues to improve on this regimen. The origin of the presumed infection is not yet clear. As a precaution, dosing of further subjects in the study has been temporarily suspended while an investigation into the cause of the event continues. This is likely to lead to a delay to the study, and the Company now expects three-month data from the extension segment of the Phase 2a study to be available in Q4, rather than Q3, of this year. The Company will provide a further update in due course.""
bradders51: joe. Have you not seen the majority of other share prices ??
zho: We have also included the milestones from Fosun for CTX and hRPC. We judge the Company has less control over the timelines for development and we therefore include only the milestones at this stage until more detail is provided. After netting off the corporate expenses and cash, we arrive at a fair value for RENE at 359 pence per share.
bigspuds: ReNeuron: refinanced and ready to riseThe biotech's recent fundraising and a good chart set-up have tempted Michael Taylor to take a position?April 21, 2021By Michael TaylorFor the second time this week, someone who has never been interested in trading or investing has asked me if they should buy a specific digital coin. Calling tops is a fool's errand. But it's safe to say the top is one day closer than it was yesterday. I've been reading Zero to One by Peter Thiel, in which the dotcom bubble is described as an 18-month frenzy. If we calculate the start of the latest bull run from April 2020, we would still have another six months of glorious speculative madness providing huge amounts of liquidity and volatility. But as we come closer and closer, the spikes go higher along with the risk. Still, we could be in for a fun summer.I have actively started moving capital into small-cap stocks that I believe have potential to weather the inevitable storm. These are uptrending and have strengthening fundamentals – stocks which I would like to add should any fast money exiting present any opportunities. Longer-term positions are now forming a part of my strategy in the stock market along with my active trading strategies that we look at in the column. I'll be posting some of these on Twitter and look forward to hearing any of your thoughts.RENE:LSEReNeuron Group PLC1mthToday change-1.29%Price (GBP)133.75One stock that I have been watching for a while is ReNeuron (RENE), a biotechnology company which researches and develops cell-based therapeutics. Drug companies can be high risk and high reward, but these risks can be mitigated depending on the company's cash position and needs, and where you enter the stock. Many UK biotech boards are poor at raising capital and end up destroying shareholder value after raising less than needed, with the idea of proving up value before raising more money later. This is a good idea in theory, but rarely works in practice. Delays are almost an inevitability and project schedules often shift (even if it is through no fault of the board).Take Phoenix Copper (PXC), which has taken the opposite approach. This is a junior mining company based in the USA, which recently raised money to finance the business with the goal of funding it through to production. The total placing shares were a whopping 73.9 percent of the existing shares – so the total number of shares in issue post placing was not far off double. It's a big dilution pill to stomach. But the advantage here is that it puts to bed any financing worries and secondly gives the board no excuses should they fail to reach production within this timeframe. While there will inevitably be the 10 per cent flippers from the placing, anyone buying now does not need to worry about a placing for the next 12 months, at least. I don't hold this stock, but it is an example of good management, in my view.ReNeuron decided to go to the market and raise £15 million last November. This gives them a runway of around 18 months – similarly ample time to get on with the job of creating value for shareholders without the worry and distraction of conducting That has not always been the case, as Chart 1 shows the stock trending sideways after a multi-year fall from 640p in 2015. I have marked with an arrow underneath a volume spike, which shows the stock rising on large volume. Perhaps this was a seller clearing and being transferred, or several trades being dealt on the back of positive news, however the stock burst through the pink 200-day exponential moving average (EMA) and formed a bull flag over the coming sessions.A bull flag is where the price consolidates sideways after a big rise, and so the rise candle is the mast, with the flag being formed in the consolidation. These are also known as pennants if the price volatility declines.We can see in Chart 1 that the stock retested the 200-day EMA resistance as support several times. This gave traders confidence that the stock was making a new trend, and I've marked the arrow when the stock broke out through this resistance. We can also see an increase of volume around this period, which was demand driving the price higher.Those that took this trade (sadly I didn't) will have made a nice multi-R gain if they had run the winner, as the stock surged 50 per cent before pausing for breath and resuming. You never know which trades will be your big winners, but by aiming to squeeze out as much juice as possible out of a trade you increase your chances of delivering high R payouts.?Moving across to Chart 2, I've marked the point with the top arrow the date where the company placed new equity at 70p. We can see in the prior months the stock selling off due to the knowledge that a placing was soon on the horizon – this is one advantage of a well-financed business, as there are no worries and therefore little stock price slippage due to people selling with the intention of reloading cheaper in the placing. The second arrow below shows the volume spike and increase in volume since that placing through the first quarter of 2021.I currently hold a position in ReNeuron, and I want to add to this should the stock break out of the 140p resistance zone. We can see a scruffy cup and handle forming on the chart which is my favourite pattern. I have no idea about the company's prospects, but the recent placing and chart combination gives me the confidence to take the trade. As with all non-profitable pharmaceutical companies it must come with a wealth warning, but for those looking to capture speculative upside in this sector I feel this could be a good entry point.Michael has started his Buy the Breakout newsletter which contains trading ideas and tips he has learned whilst trading. You can subscribe for free at his website here: @shiftingsharesNew subscribers to SharePad can claim a free month of data with the code: Michael Explore TopicsIdeasInvestment IdeasMore on Investment Ideas?April 22, 2021Big director share sales this week?April 22, 2021Macfarlane ticks the right boxes?April 22, 2021Intuitive Surgical: a cut above??April 22, 2021Ideas Farm: Infuriating intangiblesMore on Ideas?April 23, 2021Momentum investing stops working?April 22, 2021Big director share sales this week?April 22, 2021Macfarlane ticks the right boxes?April 22, 2021Intuitive Surgical: a cut above?FOLLOW US:Contact UsAbout UsHelpNearest Stockist
dickbush: There may not be much progress on the operating front but, at least, the share price is.
supernumerary: ReNeuron Group plc 07 May 2020 ReNeuron Group plc CTX cell line shows further potential ReNeuron's CTX cell line shows further potential Newly published positive efficacy data in an accepted model of Huntington's disease ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that new positive data relating to its CTX cell therapy candidate have been published in the leading peer-reviewed scientific journal Stem Cells, in a paper entitled "Implantation of the clinical-grade human neural stem cell line, CTX0E03, rescues the behavioural and pathological deficits in the quinolinic acid-lesioned rodent model of Huntington's disease". The new data show for the first time that ReNeuron's CTX human neural stem cell line can rescue deficits associated with an accepted animal model of Huntington's disease, a progressive genetic brain disorder. This study was led by Professor Jihwan Song from the Department of Biomedical Science at the CHA University in South Korea and the paper is accessible at the following link: [ ... ]
dickbush: Lauders, many thanks for that article. RENE's management has mentioned the possibility of its exosomes being useful in fighting COVID-19, but I thought it was just a try on to boost the share price. Now, if today's announcement of increased options is, heaven forbid, related to this article in the Times of Israel, we may see those option targets realised a lot sooner than 3 years. I can dream...
loafofbread: Schroder UK Public Private Tst plc Agreement for sale of assets 27/01/2021 7:00am UK Regulatory (RNS & others) Woodford Patient Capital (LSE:WPCT) Historical Stock Chart From Jan 2021 to Feb 2021 Click Here for more Woodford Patient Capital Charts. TIDMSUPP RNS Number : 9819M Schroder UK Public Private Tst plc 27 January 2021 Schroder UK Public Private Trust plc (the "Company") Agreement for sale of assets The Company (LSE: SUPP) is pleased to announce that it has signed a sale and purchase agreement for the sale of a basket of seven assets (the "Sale Portfolio") to Rosetta Capital VI, LP (the "Buyer"), an investment fund managed by the UK-based life science venture capital firm Rosetta Capital Limited, for a total acquisition price of GBP49.0 million (the "Transaction"). The Sale Portfolio consists of the Company's entire holdings in Carrick Therapeutics, Mission Therapeutics, PsiOxus Therapeutics and Mereo BioPharma and partial holdings in Inivata, Immunocore and ReNeuron. The agreed acquisition price represents a discount of 22 per cent to the aggregate valuation for those holdings reflected in the Q3 2020 Net Asset Value ("NAV") as at 30 September 2020 (as published on 3 December 2020) or a discount of 19% per cent adjusted for relevant foreign exchange rate changes as of 25 January 2021. The Buyer has also agreed to pay approximately GBP2.9 million to the Company representing the value of certain follow-on investments made by the Company with respect to holdings contained in the Sale Portfolio during January 2021. In total, the Company expects to receive initial proceeds from the Transaction of approximately GBP51.9 million. Furthermore, given the recent news of Immunocore filing for an initial public offering ("IPO"), the Company has agreed with the Buyer an earn-out under which the Company might receive an additional contingent payment of up to GBP5.0 million subject to the Immunocore stake acquired by the Buyer exceeding certain value thresholds at the Buyer's future exit of the investment. The Company had previously agreed to a lock-up period under which it would not sell its entire holding for a period of 6 months from the date of the IPO. The Buyer has agreed to be bound by the restrictions of a lock-up agreement on the same terms as the Company. The Company will remain subject to the lock-up for the proportion of the holding it is retaining. In addition, the Company and the Buyer have agreed to a potential adjustment to the acquisition price in the event of significant changes in value of the listed portfolio companies Mereo BioPharma and ReNeuron on an aggregated basis by the date of completion of the Transaction. The Company does not currently expect the potential acquisition price adjustment, if any, to be significant in the context of the overall transaction. The closing of the Transaction is subject to customary closing conditions. The Company expects the completion to occur in late February or March 2021. The valuation impact of the Transaction is expected to be reflected in the NAV of the Company as at 31 December 2020, which is expected to be announced in April 2021. A significant proportion of the expected proceeds will be used to pay down a meaningful portion of the Company's outstanding debt under its credit facility whereby the current term loan will convert to a revolving credit facility. In addition, the Company intends to use the additional liquidity to support some of its portfolio companies with follow-on capital and further optimise the portfolio composition by selectively investing into new opportunities Tim Creed and Ben Wicks, Portfolio Managers of the Company, jointly commented: "After the announcement of the acquisition of Kymab by Sanofi and the extension of the Company's credit facility by two years, this is the third very positive announcement for the Company so far in 2021. When we assumed the management of the Company's investment portfolio in December 2019, we communicated that our initial focus in the process of repositioning the portfolio would be to reduce the outstanding debt to a sustainable level and put the Company back into a position to support its portfolio companies with follow-on capital and selectively make new investments. The basket transaction being announced today is a further important milestone for the Company and delivers against that communicated goal. Together with the divestiture of Kymab, the Company expects to receive total proceeds of more than GBP115 million by the end of the first half of 2021. Also, we are delighted to welcome Rosetta Capital as co-shareholders in ReNeuron, Immunocore and Inivata and we welcome their expertise and experience. We are looking forward to continuing to work with the management teams of the Company's holdings in delivering sustainable value and positive long-term shareholder returns." Susan Searle, Chair of the Board of the Company, commented: "I am extremely pleased with the progress that Schroders have made since taking over the management of the portfolio. The three announcements made in 2021; the extension of our debt facility, a significant portfolio company cash exit and a portfolio sale put the Company in a solid position from which to grow in 2021. These events reflect the hard work of the team throughout 2020 and I look forward to seeing the team build on this encouraging positive progress in repositioning the Company's portfolio." Enquiries: Schroder Investment Management Limited
Reneuron share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210625 06:31:20